Jiangsu Hengrui Pharmaceuticals (600276.SH): The clinical trial application for Fruquichuzhu monoclonal antibody injection has been approved.
Hengrui Medicine (600276.SS) issued an announcement that its subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., has received a...
Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that its subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., has received the approval notification from the National Medical Products Administration for the clinical trials of the injection of Fuzhao Chi Zhu monoclonal antibody. The company will soon start the clinical trials. Fuzhao Chi Zhu monoclonal antibody injection is a recombinant humanized monoclonal antibody that targets human IL-17A, developed by the company, intended for the treatment of autoimmune diseases related to the IL-17 pathway.
Related Articles
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
